Independent Director · Entrada Therapeutics, Inc. (TRDA)

Bernhardt Zeiher, M.D — Entrada Therapeutics Director Compensation (2025)

Fiscal year 2025 director compensation for Bernhardt Zeiher, M.D at Entrada Therapeutics, Inc.. Every figure below is printed as the company filed it and cited to the filing it came from.

Director compensation as of the proxy filed April 24, 2026 (DEF 14A). Open the filing on EDGAR.

Free

Get Bernhardt Zeiher, M.D’s full pay file as a PDF — free

More than this page: up to 10 years of Bernhardt’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Bernhardt Zeiher, M.D and every company like it: Velarion Intel, free for 3 days, no card →

What they were paid

Entrada Therapeutics Director Compensation Table · all 2 fiscal years held
In US dollars, as Entrada Therapeutics reports it. Most recent year first. Totals are the company’s disclosed totals.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$46,291$0$104,388$0$150,680
FY2023$33,122—$300,896$0$334,018

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Entrada Therapeutics, Inc. DEF 14A filed April 24, 2026, accession 0001689375-26-000021, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Entrada Therapeutics, Inc. filed document, accession 0001689375-26-000021. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.

Get the Entrada Therapeutics Board Governance Report

$150,680 Bernhardt Zeiher, M.D, FY2025 total director compensation

$500

The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.

Data as of April 24, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

How this board is paid

company policy · FY2025

Entrada Therapeutics pays directors a $40,000 cash retainer and $250,000 in equity.

Committees

FY2025 · as the proxy prints them

Compensation

The rest of the Entrada Therapeutics board

FY2025 · as the company reported each
DirectorRoleFY2025 total
Gina ChapmanIndependent Director$157,553
Kush M. Parmar, M.D., Ph.DIndependent Director$202,597
Maha Radhakrishnan, M.DIndependent Director$230,927
Mary ThistleIndependent Director$167,427
Peter S. Kim, Ph.DDirector$144,388

The full Entrada Therapeutics compensation record

free company brief

This page is one director within Entrada Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.

Order TRDA

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Board Governance Report